Atorvastatin
- Generic Name
- Atorvastatin
- Brand Names
- Atorvaliq, Caduet, Lipitor, Lypqozet
- Drug Type
- Small Molecule
- Chemical Formula
- C33H35FN2O5
- CAS Number
- 134523-00-5
- Unique Ingredient Identifier
- A0JWA85V8F
- Background
Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylg...
- Indication
Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.
...
- Associated Conditions
- Anginal Pain, Cardiovascular Complications, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Coronary artery thrombosis, Dysbetalipoproteinemia, Fredrickson Type III lipidemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hospitalizations, Hypertension, Essential Hypertension, Hypertriglyceridemias, Mixed Dyslipidemias, Mixed Hyperlipidemia, Myocardial Infarction, Non-familial hypercholesterolemia, Nonfatal Myocardial Infarction, Postoperative Thromboembolism, Primary Hypercholesterolemia, Stroke, Thrombosis, Transient Ischemic Attack, Elevation of serum triglyceride levels, Heterozygous familial hyperlipidemia, Non-familial hyperlipidemia, Primary Hyperlipidemia, Revascularization procedures
- Associated Therapies
- -
Atorvastatin Effect on Contrast Induced Nephropathy in Diabetic Patients Undergoing Elective Coronary Intervention
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Mohamed Abdelfatah
- Target Recruit Count
- 200
- Registration Number
- NCT04375787
- Locations
- 🇪🇬
Assiut University, Assiut, Egypt
A Study of LY3478045 in Healthy Participants
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 72
- Registration Number
- NCT04270370
- Locations
- 🇺🇸
Covance Dallas, Dallas, Texas, United States
Treatment of Chronic Mountain Sickness
- Conditions
- Interventions
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Centre d'Expertise sur l'Altitude EXALT
- Target Recruit Count
- 60
- Registration Number
- NCT04251364
- Locations
- 🇫🇷
Association EXALT, UM Sport Pathologies, Hôpital Sud, Avenue Kimberley, Échirolles, France
Statin Treatment for UnruptureD Intracranial anEurysms Study
- Conditions
- Interventions
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- Beijing Neurosurgical Institute
- Target Recruit Count
- 60
- Registration Number
- NCT04149483
- Locations
- 🇨🇳
Beijing Neurosurgical Institute and Beijing Tiantan Hospital, Beijing, Beijing, China
Atorvastatin vs Colchicine in Decrease of Troponin I of High Sensitivity in Patients With Rheumatoid Arthritis.
- Conditions
- Interventions
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Hospital Central "Dr. Ignacio Morones Prieto"
- Target Recruit Count
- 60
- Registration Number
- NCT04056039
- Locations
- 🇲🇽
Hospital Central "Dr Ignacio Morones Prieto", San Luis Potosí, Mexico
A Study of LY900020 in Healthy Chinese Participants
- Conditions
- Interventions
- First Posted Date
- 2019-08-07
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT04047940
- Locations
- 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore
A Study of LY3502970 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2019-04-29
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 133
- Registration Number
- NCT03929744
- Locations
- 🇺🇸
Covance Dallas, Dallas, Texas, United States
Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019)
- Conditions
- Interventions
- First Posted Date
- 2019-03-22
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 44
- Registration Number
- NCT03885921
Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)
- Conditions
- Interventions
- First Posted Date
- 2019-03-21
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 50
- Registration Number
- NCT03884452
A Long-term Safety and Tolerability Study of Ezetimibe Plus Atorvastatin in Participants With Coronary Heart Disease, Multiple Risk Factors, or Hypercholesterolemia Not Controlled by Atorvastatin (P01418/MK-0653-032)
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 432
- Registration Number
- NCT03882996
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.